Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C317/00—Sulfones; Sulfoxides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
  • C07D215/60—N-oxides

Definitions

• Heterocycle-N-oxide-substituted benzoylguanidines processes for their preparation, their use as medicaments or diagnostic agents, medicaments containing them and intermediates for their production
• heteroaryl are understood in particular radicals which are derived from phenyl or naphthyl, in which one or more CH groups have been replaced by N and / or in which at least two adjacent CH groups (to form a five-membered aromatic Rings) are replaced by S, NH or O. Furthermore, one or both atoms of the condensation site of bicyclic radicals (as in indolizinyl) can also be N atoms.
• Heteroaryl-N-oxide are especially imidazolyl-N-oxide, pyrazolyl-N-oxide, triazolyl-N-oxide, tetrazolyl-N-oxide, oxazolyl-N-oxide, isoxazolyl-N-oxide, thiazolyl-N-oxide, Isothiazolyl N oxide, pyridyl N oxide, pyrazinyl N oxide, pyrimidinyl N oxide, pyridazinyl N oxide, indazolyl N oxide, quinolyl N oxide, isoquinolyl N oxide, phthalazinyl N-oxide, quinoxalinyl-N-oxide, quinazolinyl-N-oxide, cinnolinyl-N-oxide.
• R (1) to R (5) one or more Asymmetry centers, these can be configured both S and R.
• the compounds can exist as optical isomers, as diastereomers, as racemates or as mixtures thereof.
• the specified alkyl and perfluoroalkyl radicals can be either straight-chain or branched.
• the invention further relates to a process for the preparation of the compounds of formula I, characterized in that a compound of formula II reacted with guanidine, in which L stands for an easily nucleophilically substitutable leaving group.
• An activated carboxylic acid derivative of the formula I is reacted with guanidine in a manner known per se in a protic or aprotic polar but inert organic solvent.
• Most reactions of compounds II with salt-free guanidine have advantageously been carried out in inert solvents such as THF, dimethoxyethane, dioxane or isopropanol. But water can also serve as a solvent.
• the unknown compounds of formula II can be prepared by methods known from the literature, for example by using 4-halo-3-chlorosulfonylbenzoic acids with ammonia or amines in 3-aminosulfonyl-4-halogeno-benzoic acids or with a weak reducing agent such as Sodium bisulfite and subsequent alkylation are converted into 3-alkylsulfonyl-4-halogeno-benzoic acids and converted into compounds I according to the invention by one of the process variants described above.
• Substituted sulfur, oxygen or nitrogen nucleophiles can be introduced using methods known from the literature for nucleophilic substitution on aromatics. Halides and trifluoromethanesulfonates have proven themselves as leaving groups in this substitution.
• the process is advantageously carried out in a dipolar aprotic solvent, such as DMF or TMU, at a temperature between 0 ° C. and the boiling point of the solvent, preferably between 80 ° C. and the boiling point of the solvent.
• An alkali or alkaline earth salt with an anion of high basicity and low nucleophilicity, such as K2CO3 or CsCO3, is advantageously used as the acid scavenger.
• alkyl or aryl substituents can be introduced by methods known from the literature of palladium-mediated cross-coupling of aryl halides with, for example, organozinc compounds, organostannanes, organoboronic acids or organoboranes.
• the nitrogen in the heteroaryl substituent can be oxidized using suitable intermediates such as the benzoic acid ester using methods known in principle.
• suitable intermediates such as the benzoic acid ester using methods known in principle.
• m-chloroperbenzoic acid has proven itself in an inert solvent such as methylene chloride at a temperature between - 30 ° C and the boiling point of the solvent.
• Benzoylguanidines I are generally weak bases and can bind acid with the formation of salts.
• Suitable acid addition salts are salts of all pharmacologically acceptable acids, for example halides, in particular hydrochlorides, lactates, sulfates, citrates, tartrates, acetates, phosphates, methyl sulfonates, p-toluenesulfonates.
• the compounds I are substituted acylguanidines.
• the most prominent representative of the acylguanidines is the pyrazine derivative amiloride, which is used as a potassium-saving diuretic in therapy.
• the compounds according to the invention have no undesirable and disadvantageous salidiuretic, but very good antiarrhythmic properties which are important in the treatment of diseases such as those which occur, for example, in the case of oxygen deficiency symptoms.
• the compounds are outstandingly suitable as antiarrhythmic medicaments with cardioprotective components for the prevention of infarction and the treatment of infarction, and for the treatment of angina pectoris, and they also prevent or inhibit the pathophysiological processes in the occurrence of ischemically induced damage, particularly when triggering ischemically induced cardiac arrhythmias greatly decrease.
• the compounds of the formula I according to the invention can be used as a medicament for the treatment of all acute or chronic damage caused by ischemia or diseases which are primarily or secondarily induced thereby.
• This relates to their use as medicines for surgical interventions, for example in organ transplants, the compounds both for protecting the organs in the donor before and during removal, for protecting removed organs, for example during treatment with or their storage in physiological bath fluids, and also can be used for the transfer into the recipient organism.
• the compounds are also valuable, protective drugs when performing angioplasty surgery, for example on the heart as well as on peripheral vessels.
• the compounds are also suitable as medicaments for the treatment of ischemia of the nervous system, in particular the central nervous system eg suitable for the treatment of stroke or brain edema.
• the compounds of the formula I according to the invention are also suitable for treating forms of shock, such as, for example, allergic, cardiogenic, hypovolemic and bacterial shock.
• the compounds of the formula I according to the invention are notable for a strong inhibitory effect on the proliferation of cells, for example fibroblast cell proliferation and the proliferation of smooth vascular muscle cells.
• the compounds of the formula I are therefore useful therapeutic agents for diseases in which cell proliferation is a primary or secondary cause and can therefore be used as antiatherosclerotic agents, agents for late diabetic complications, cancer, fibrotic diseases such as pulmonary fibrosis, liver fibrosis or kidney fibrosis, organ hypertrophies and - hyperplasias, especially for prostate hyperplasia or prostate hypertrophy.
• the compounds according to the invention are effective inhibitors of the cellular sodium proton antiporter (Na+ / H+ exchanger), which is increased in numerous diseases (essential hypertension, atherosclerosis, diabetes, etc.) even in cells which are easily accessible, such as in erythrocytes, thrombocytes or leukocytes.
• the compounds according to the invention are therefore suitable as excellent and simple scientific tools, for example in their use as diagnostics for determining and distinguishing certain forms of hypertension, but also atherosclerosis, diabetes, proliferative diseases, etc.
• the compounds of the formula I are for preventive therapy is suitable for preventing the genesis of high blood pressure, for example essential hypertension.
• the compounds according to the invention have significantly improved water solubility. Therefore, they are much better suited for IV applications.
• Medicaments containing a compound I can be administered orally, parenterally, intravenously, rectally or by inhalation, the preferred application depending on the particular appearance of the disease.
• the compounds I can be used alone or together with pharmaceutical auxiliaries, both in veterinary and in human medicine.
• auxiliaries which are suitable for the desired pharmaceutical formulation on the basis of his specialist knowledge.
• solvents for example antioxidants, dispersants, emulsifiers, defoamers, taste correctives, preservatives, solubilizers or colorants can be used.
• the active compounds are mixed with the suitable additives, such as carriers, stabilizers or inert diluents, and brought into suitable dosage forms by the usual methods, such as tablets, dragées, push-fit capsules, aqueous, alcoholic or oily solutions.
• suitable additives such as carriers, stabilizers or inert diluents
• suitable dosage forms by the usual methods, such as tablets, dragées, push-fit capsules, aqueous, alcoholic or oily solutions.
• inert carriers such.
• the preparation can take place both as dry and as moist granules.
• Vegetable or animal oils such as sunflower oil or cod liver oil, are suitable as oily carriers or as solvents.
• the active compounds are brought into solution, suspension or emulsion, if desired with the usual substances such as solubilizers, emulsifiers or other auxiliaries.
• solvents such as water, physiological saline or alcohols, e.g. As ethanol, propanol, glycerol, and also sugar solutions such as glucose or mannitol solutions, or a mixture of the various solvents mentioned.
• Suitable pharmaceutical formulations for administration in the form of aerosols or sprays are, for. B. solutions, suspensions or emulsions of the active ingredient of formula I in a pharmaceutically acceptable solvent, such as in particular ethanol or water, or a mixture of such solvents.
• a pharmaceutically acceptable solvent such as in particular ethanol or water, or a mixture of such solvents.
• the formulation can also contain other pharmaceutical auxiliaries such as surfactants, emulsifiers and stabilizers and a propellant.
• Such a preparation usually contains the active ingredient in a concentration of approximately 0.1 to 10, in particular approximately 0.3 to 3% by weight.
• the dosage of the active ingredient of formula I to be administered and the frequency of administration depend on the potency and duration of action of the compounds used; also on the type and severity of the disease to be treated and on the sex, age, weight and individual responsiveness of the mammal to be treated.
• the daily dose of a compound of the formula I in a patient weighing approximately 75 kg is at least 0.001 mg / kg, preferably 0.01 mg / kg, to at most 10 mg / kg, preferably 1 mg / kg body weight.
• more frequent doses may be necessary, for example up to 4 individual doses per day.
• up to 200 mg per day may be necessary.
• 0.01 M of the benzoic acid derivative of the formula II is dissolved or suspended in 60 ml of anhydrous THF and then mixed with 1.78 g (0.011 M) of carbonyldiimidazole. After stirring for 2 hours at RT, 2.95 g (0.05 M) of guanidine are introduced into the reaction solution. After stirring overnight, the THF is distilled off under reduced pressure (in a rotary evaporator), water is added, the pH is adjusted to 6 to 7 with 2N HCl and the corresponding benzoylguanidine (formula I) is filtered off.
• the benzoylguanidines thus obtained can be treated with aqueous, methanolic or ethereal hydrochloric acid or other pharmacologically acceptable acids are converted into the corresponding salts.
• Example 3 The compound of Example 3 was synthesized analogously to Example 2:
• White New Zealand rabbits received a standard diet with 2% cholesterol for six weeks to activate the Na+ / H+ exchange and thus the Na+ influx into the erythrocytes via Na+ / H+ exchange by flame photometry to be able to determine.
• the blood was taken from the ear arteries and made non-coagulable by 25 IU potassium heparin. A portion of each sample was used to duplicate the hematocrit by centrifugation. Aliquots of 100 ⁇ l each were used to measure the initial Na+ content of the erythrocytes.
• the net Na+ influx was calculated from the difference between the initial sodium values and the sodium content of the erythrocytes after incubation.
• the amiloride-inhibitable sodium influx resulted from the difference in the sodium content of the erythrocytes after incubation with and without amiloride 3 x 10 ⁇ 4 mol / l.
• the same procedure was followed for the compounds according to the invention.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Diabetes (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Gastroenterology & Hepatology (AREA)
• Surgery (AREA)
• Hematology (AREA)
• Vascular Medicine (AREA)
• Reproductive Health (AREA)
• Emergency Medicine (AREA)
• Pulmonology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Quinoline Compounds (AREA)
• Pyridine Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=6527788

Family Applications (1)

Country Status (22)

Cited By (3)

Families Citing this family (8)

Citations (11)

Family Cites Families (2)

• 1994
  • 1994-09-09 DE DE4432106A patent/DE4432106A1/de not_active Withdrawn
• 1995
  • 1995-09-04 AT AT95113845T patent/ATE210121T1/de not_active IP Right Cessation
  • 1995-09-04 ES ES95113845T patent/ES2168324T3/es not_active Expired - Lifetime
  • 1995-09-04 EP EP95113845A patent/EP0700904B1/fr not_active Expired - Lifetime
  • 1995-09-04 DE DE59509899T patent/DE59509899D1/de not_active Expired - Lifetime
  • 1995-09-04 PT PT95113845T patent/PT700904E/pt unknown
  • 1995-09-04 DK DK95113845T patent/DK0700904T3/da active
  • 1995-09-06 IL IL11519695A patent/IL115196A/xx active IP Right Grant
  • 1995-09-06 CN CN95116297A patent/CN1119643A/zh active Pending
  • 1995-09-07 NZ NZ272946A patent/NZ272946A/en unknown
  • 1995-09-07 RU RU95115511/04A patent/RU2160727C2/ru not_active IP Right Cessation
  • 1995-09-07 AU AU30504/95A patent/AU695342B2/en not_active Ceased
  • 1995-09-07 FI FI954190A patent/FI954190A/fi unknown
  • 1995-09-07 KR KR1019950029358A patent/KR960010619A/ko not_active Application Discontinuation
  • 1995-09-08 SI SI9500280A patent/SI9500280B/sl unknown
  • 1995-09-08 PL PL95310346A patent/PL310346A1/xx unknown
  • 1995-09-08 CA CA002157855A patent/CA2157855C/fr not_active Expired - Fee Related
  • 1995-09-08 CZ CZ19952315A patent/CZ291188B6/cs not_active IP Right Cessation
  • 1995-09-08 JP JP23096695A patent/JP4113262B2/ja not_active Expired - Fee Related
  • 1995-09-08 HU HU9502634A patent/HU219976B/hu not_active IP Right Cessation
  • 1995-09-08 NO NO953555A patent/NO305202B1/no unknown
  • 1995-09-08 ZA ZA957548A patent/ZA957548B/xx unknown
  • 1995-09-08 US US08/525,156 patent/US5641792A/en not_active Expired - Lifetime

Patent Citations (11)

Non-Patent Citations (6)

Also Published As

Similar Documents

Legal Events